Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: Results of clinical and pharmacoeconomic analysis

Antibiotiki i Khimioterapiya

Volumn 51, Issue 7, 2006, Pages 15-27

  Yakovlev, S V ^a   Beloborodov, V B ^a   Sidorenko, S V ^a   Yakovlev, V P ^a   Grigoryev, K B ^a   Eliseeva, E V ^a   Kon, E M ^a   Levit, A L ^a   Kostina, G V ^a   Kuprenkov, A V ^a   Mukhacheva, S Yu ^a   Saturnov, A V ^a   Sergeev, I N ^a   Spasov, G P ^a   Stakanov, A V ^a   Ushakova, M A ^a  

^a Alliance of Clinical Chemotherapeutists and Microbiologists   (Russian Federation)

Author keywords

Combined therapy; Cost effectiveness analysis; Meropenem; Severe nosocomial infection

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; MEROPENEM; METRONIDAZOLE; QUINOLONE DERIVATIVE; THIENAMYCIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; CROSS INFECTION; DRUG COMBINATION; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAMS; COSTS AND COST ANALYSIS; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RUSSIA; THIENAMYCINS; TREATMENT OUTCOME;

ACINETOBACTER; ESCHERICHIA COLI;

EID: 34547378030     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Vincent J. L., Bihardi D. J., Suter P. M. et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 8: 639-644.
2. Richards M. J., Edwards J. R., Culver D. H., Gaynes R. P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 5: 887-892.
3. Rello J., Ollendorf D.A., Oster G. et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 6: 2115-2122.
4. Kollef M. H. Appropriate empirical antibacterial therapy for nosocomial infections. Drugs 2003; 63: 20: 2157-2168.
5. Kollef M. H. Inadequate antimicrobial treatment: an inmortante determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31: Suppl 4: 131-138.
6. Trouillet J-L., Chastre J., VuagnatA. et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 2: 531-539.
7. Cosgrove S. E., Kaye K. S., Eliopoulous G. M., Carmelli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 1: 185-190.
8. Luna C. M., Vujacich P., Niederman M. S. et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
9. Iregui M., Ward S., Sherman G. et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
10. Ibrahim E. H., Sherman G., Ward S. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.
11. Russian source
12. Russian source
13. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 4: 388-416.
14. Solomkin J. S., Maztiski J. E., Baron E. J. et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
15. Kollef M. H., Sherman G., Ward S. et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
16. Paterson D. L. Recomendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Clin Microbiol Infect 2000; 6: 460-463.
17. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22: 387-394.
18. Kollef M. H. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004; 49: 12: 1530-1541.